Abstract

We thank Lisa Grech and colleagues for their Correspondence concerning our Article on the MS-SMART trial. This multiarm phase 2b trial effectively condensed, into one well powered trial, the study of three re-purposed drugs with distinct mechanisms of action potentially relevant to slowing progression in secondary progressive multiple sclerosis. Despite positive experimental and early clinical work, unfortunately none of the drugs had any effect on slowing the rate of whole-brain atrophy (primary outcome), nor on a variety of secondary outcome measures.
Original languageEnglish
Pages (from-to)479-480
Number of pages2
JournalLancet Neurology
Volume19
Issue number6
DOIs
Publication statusPublished - 1 Jun 2020

Fingerprint

Dive into the research topics of 'MS-SMART study: systematic sampling bias concerns - Authors' reply'. Together they form a unique fingerprint.

Cite this